<DOC>
	<DOCNO>NCT02551991</DOCNO>
	<brief_summary>This open-label , phase 2 comparative study ass safety , tolerability , efficacy nal-IRI combination anticancer therapy , compare nab-paclitaxel + gemcitabine , patient advance pancreatic adenocarcinoma receive prior chemotherapy . This study ass follow regimen : - nal-IRI + 5-FU/LV + oxaliplatin - nal-IRI + 5-FU/LV - nab-paclitaxel + gemcitabine The study conduct two part : 1. safety run-in nal-IRI + 5-FU/LV + oxaliplatin regimen , 2. randomize , efficacy study nal-IRI + 5-FU/LV + oxaliplatin , nal-IRI + 5-FU/LV , versus nab-paclitaxel + gemcitabine .</brief_summary>
	<brief_title>Study Nanoliposomal Irinotecan ( Nal-IRI ) -Containing Regimens Patients With Previously Untreated , Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma pancreas previously treat metastatic set Part 1 : Unresectable , locally advanced metastatic disease ; diagnose within 6 wks prior enrollment ; Part 2 : Metastatic disease ; diagnose within 6 wks prior randomization Measurable nonmeasurable disease define RECIST v1.1 ECOG performance 0 1 Adequate hematological , hepatic , renal cardiac function Prior treatment pancreatic cancer metastatic setting surgery ( placement stent allow ) , radiotherapy , chemotherapy investigational therapy Prior treatment pancreatic cancer chemotherapy ( radiation sensitizer allow â‰¥ 6 month elapse completion ) Uncontrolled CNS metastasis Clinically significant gastrointestinal disorder History second malignancy last 3 year . Patients prior history insitu cancer basal squamous cell skin cancer eligible Presence contraindication nalIRI , irinotecan , 5FU , leucovorin , oxaliplatin , nabpaclitaxel ( part 2 ) gemcitabine ( part 2 ) Use strong CYP3A4 CYP2C8 inhibitor inducer ( part 2 ) Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>MM-398</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>First line pancreatic cancer treatment</keyword>
</DOC>